Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading

Open Interest and Volume Dynamics

The open interest (OI) in Mankind Pharma’s futures and options contracts rose sharply from 17,362 to 22,188 contracts, an increase of 4,826 contracts or 27.8% on the day. This surge in OI was accompanied by a robust volume of 36,415 contracts traded, indicating strong participation from both institutional and retail investors. The futures value stood at approximately ₹21,750 lakhs, while the options segment recorded an enormous notional value of ₹15,788.65 crores, culminating in a total derivatives value of ₹24,291 lakhs.

This combination of rising OI and high volume typically suggests fresh positions are being established rather than existing ones being squared off, pointing to increased conviction among traders regarding the stock’s near-term direction.

Price Action and Volatility Context

On the same day, Mankind Pharma’s stock price closed at ₹2,084, just 1.88% above its 52-week low of ₹2,046.8. The stock experienced an intraday low of ₹2,057.1, down 4.88% from the previous close, reflecting significant selling pressure. The weighted average price of traded shares was closer to the day’s low, underscoring bearish sentiment during the session.

Volatility was elevated, with an intraday range of 5.16%, highlighting the stock’s sensitivity to market developments and investor sentiment. Notably, Mankind Pharma traded below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating a sustained downtrend and weak technical positioning.

Investor Participation and Liquidity

Investor engagement has intensified, as evidenced by a delivery volume of 4.16 lakh shares on 3 Feb 2026, which surged by 93.43% compared to the five-day average delivery volume. This rise in delivery volume suggests that more investors are holding shares rather than trading intraday, potentially signalling accumulation or defensive positioning amid price weakness.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting transactions up to ₹1.97 crore without significant market impact. This liquidity profile is crucial for derivatives traders looking to enter or exit positions efficiently.

Market Positioning and Directional Bets

The sharp rise in open interest alongside a declining stock price and heavy volume suggests that market participants are actively repositioning. The increase in OI while prices fall often indicates that fresh short positions are being built, reflecting bearish sentiment. However, the elevated delivery volumes hint at some investors possibly accumulating shares at lower levels, anticipating a potential rebound or defensive holding.

Given Mankind Pharma’s current Mojo Score of 38.0 and a downgrade from Hold to Sell on 19 Nov 2025, the market’s cautious stance is understandable. The company’s market cap stands at a substantial ₹86,198 crore, classifying it as a large-cap stock, yet its Market Cap Grade is rated 1, signalling limited upside from a valuation perspective.

Comparatively, the stock underperformed its Pharmaceuticals & Biotechnology sector by 3.39% on the day, while the broader Sensex gained 0.32%, highlighting sector-specific headwinds or company-specific concerns driving the sell-off.

Technical and Fundamental Outlook

Trading below all major moving averages and near its 52-week low, Mankind Pharma faces significant technical resistance. The high volatility and volume spikes suggest that the stock is at a critical juncture where either a further decline or a technical bounce could materialise depending on broader market cues and company fundamentals.

Fundamentally, the downgrade to Sell by MarketsMOJO reflects concerns over growth prospects or valuation pressures. Investors should weigh these factors carefully, especially given the stock’s current weak momentum and the derivatives market’s positioning.

Implications for Investors and Traders

For derivatives traders, the surge in open interest combined with elevated volumes and price weakness suggests a predominance of bearish bets, possibly through futures short positions or put options. However, the sizeable delivery volumes indicate that some investors may be taking a longer-term view, accumulating shares at depressed prices.

Investors should monitor upcoming quarterly results, sector developments, and broader market trends to gauge whether the current positioning will translate into sustained price moves. The stock’s liquidity and active derivatives market provide ample opportunity for tactical trades, but caution is warranted given the prevailing downtrend and negative mojo rating.

Overall, Mankind Pharma’s recent market activity reflects a complex interplay of bearish sentiment and selective accumulation, underscoring the importance of a nuanced approach to trading and investment decisions in this pharmaceutical heavyweight.

Unlock special upgrade rates for a limited period. Start Saving Now →